iBio, Inc. (NYSE AMEX: IBIO) announced that an open house for sell-side analysts and institutional fund managers will be held on June 16, 2011, at its Newark, Delaware headquarters, commencing at 10:00 A.M. (Eastern time).
The event will include an opportunity to view a state-of-the-art, GMP-compliant, plant-based pilot manufacturing facility that demonstrates the use and attributes of the iBioLaunch™ Platform. A presentation by iBio senior management also will be offered during the open house.
For registration and further information, please contact Mr. Douglas Hicks, iBio’s Vice President of Business Development, at email@example.com.
About iBio, Inc.iBio develops and offers product applications of its iBioLaunch platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. Further information is available at: www.ibioinc.com.